CORE--ADHERENCE TO HIV MEDICATION

艾滋病毒感染的治疗已经从根本上改变了，使用了 联合抗逆转录病毒化疗，包括蛋白酶抑制剂。 这些药物与逆转录酶抑制剂结合可产生 血浆病毒RNA大幅下降，CD/4计数增加， 改善临床结果。这种疗法提供了长时间的前景 长期存活，甚至根除疾病。同时，如果这些 服药量不足，或服药方案剂量 不规则，治疗效益丧失和抗病毒耐药性 发展起来。蛋白酶抑制剂需要严格的给药计划，大多数 通常添加到本已复杂的药物治疗方案中。此外，这些 药物会产生麻烦的副作用，而且有很大的药效 互动。经常服用这些药物的患者是功能性的 健康状况不佳，可能有认知障碍。这些 因素使艾滋病毒疾病的成功治疗不再是一个 有效的药物疗法的可用性，并更多地依赖于 患者能够长期坚持复杂的药物治疗方案。 然而，衡量抗逆转录病毒依从性的严格方法 药物并不是很普遍，大多数临床试验都采用了 对服药依从性的最小评估(如果有的话)。 药物依从性核心正在验证基于访谈的方法，以 根据新开发的项目和在ACTG中完成的工作来衡量遵守情况 和HCSUS的研究。这些仪器测量患者对工作的忠诚度。 加州大学洛杉矶分校的艾滋病毒临床试验和队列研究，以(1)确定 衡量服药依从性的机会，(2)提供和定制 用于纳入现有和计划中的研究的工具。(3) 协助设计数据收集和分析策略，以衡量 依从性和与依从性相关的因素，以及(4)先前的适应 适用于新人群(如儿科)和 临床环境。此外，药物依从性核心将发挥作用 与临床试验研究人员共同开发干预措施，以增强 并衡量这些干预措施的效果。此外, 有了行为遵守招募和保留核心，这一核心 将创建连贯的医疗和行为评估模块 加州大学洛杉矶分校调查人员的坚持。这两个核心将构成健康 CFAR的行为和外展计划。

The treatment of HIV infection has been radically altered by the use of combination anti-retroviral chemotherapy including protease inhibitors. These agents in combination with reverse transcriptase inhibitors produce profound declines in plasma viral RNA, increases in CD/4 counts and improved clinical outcomes. This therapy provides the prospect for long term survival and even disease eradication. At the same time, if these medications are taken in inadequate amount or if the regimen dosing is irregular, the therapeutic benefit is lost and antiviral resistance develops. Protease inhibitors require rigorous dosing schedules, most commonly added to already complex medications regimens. Furthermore, these medications cause trouble side effects and have substantial drug interactions. The patients taking these medications often are functionally compromised with poor health status and may be cognitively impaired. These factors makes the successful treatment of HIV disease less an issue of the availability of potent pharmacological therapeutics and more dependent on patient ability to adhere to a complex medication regiment over time. However, rigorous methods of measuring adherence to anti-retroviral medication are not widely available and most clinical trials have employed minimal, if any, evaluation of medication adherence. The Medication Adherence Core is validating interview-based methodology to measure adherence based on newly developed items and work done in the ACTG and HCSUS studies. These instruments measure patient adherence to work with HIV clinical trials and cohort studies at UCLA to (1) identify opportunities to measure medication adherence, (2) provide and customize instruments for incorporation into existing and planned studies. (3) assist in design of data collection and analysis strategies to measure adherence and factors associated with adherence, and (4) adapt previously validated instruments for new populations (such as pediatrics) and clinical settings. In addition, the Medication Adherence Core will work with clinical trial investigators to develop interventions to enhance adherence and to measure the effects of these interventions. In addition, with the Behavioral Adherence Recruitment and Retention Core, this Core will create coherent assessment modules of medical and behavioral adherence for UCLA investigators. Both Cores will constitute the Health Behavior and Outreach Program of the CFAR.